Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/10732
Title: To stop or not to stop, that is the question.
Authors: Seeman, Ego
Affiliation: egos@unimelb.edu.au
Department of Endocrinology, Austin Health, University of Melbourne, Australia
Issue Date: 1-Feb-2009
Citation: Osteoporosis International : A Journal Established As Result of Cooperation Between the European Foundation For Osteoporosis and the National Osteoporosis Foundation of The Usa; 20(2): 187-95
Abstract: Treatment aimed at preventing fractures should be stopped if evidence of continued antifracture efficacy is lacking, if continued treatment increases bone fragility by adversely affecting matrix properties, and if stopping does not increased bone fragility. Credible evidence of antifracture efficacy beyond 5 years is lacking because of attrition of the cohort originally allocated to treatment or placebo and lack of controls. Prolonged suppression of remodeling is associated with accumulation of microdamage, advanced glycation products and increased tissue mineral density in animal studies but the structural benefits appear to out weight these adverse effects. Atypical minimal trauma subtrochanteric fractures are associated with prolonged treatment in human subjects but these are exceedingly rare. Stopping treatment does result in the reemergence of remodeling, rapidly with some drugs, more slowly with others while fracture rates are increased in poor compliers to treatment. Thus, within the constraints of limited evidence, I infer that stopping therapy is more likely to do net harm than continuing therapy - treatment should be continued in the majority of individuals.
Internal ID Number: 19096746
URI: http://ahro.austin.org.au/austinjspui/handle/1/10732
DOI: 10.1007/s00198-008-0813-x
URL: http://www.ncbi.nlm.nih.gov/pubmed/19096746
Type: Journal Article
Subjects: Aged
Bone Density.drug effects
Bone Density Conservation Agents.therapeutic use
Bone Remodeling.drug effects
Diphosphonates.therapeutic use
Female
Fractures, Bone.prevention & control
Humans
Middle Aged
Osteoporosis, Postmenopausal.drug therapy
Refusal to Treat
Time Factors
Treatment Outcome
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
19096746.pdf61.15 kBAdobe PDFView/Open


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.